{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"To evaluate the efficacy of chemotherapy in preserving renal units in children with diffuse hyperplastic perilobar nephroblastomatosis (DHPLN) and preventing Wilms tumor development.","groups":[{"description":"Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.","id":"OG000","title":"Arm 3 (DHPLN)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and evaluable patients with diffuse hyperplastic perilobar nephroblastomatosis (DPHLN).","reportingStatus":"POSTED","timeFrame":"12 weeks from the study entry","title":"Number of Patients Without Complete Removal of at Least One Kidney","type":"PRIMARY","unitOfMeasure":"Participants"}